Citric acid inhibits development of cataracts, proteinuria and ketosis in streptozotocin (type 1) diabetic rats

Biochemical and Biophysical Research Communications

Volumn 393, Issue 1, 2010, Pages 118-122

  Nagai, Ryoji ^a   Nagai, Mime ^a   Shimasaki, Satoko ^a   Baynes, John W ^b   Fujiwara, Yukio ^c  

^a JAPAN WOMEN'S UNIVERSITY   (Japan)

^b UNIVERSITY OF SOUTH CAROLINA   (United States)

^c KUMAMOTO UNIVERSITY   (Japan)

Author keywords

Advanced glycation end product (AGEs); Cataract; Diabetes; Ketosis; N (carboxyethyl)lysine (CEL); Nephropathy

Indexed keywords

6 N CARBOXYMETHYLLYSINE; ACETOLACTATE SYNTHASE; ACETONE; ACETONE MONOOXYGENASE; CITRIC ACID; GLUCOSE; INSULIN; LENS PROTEIN; UNCLASSIFIED DRUG;

ALBUMINURIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CATARACT; CONTROLLED STUDY; DIABETES MELLITUS; DRUG DOSE INCREASE; DRUG EFFECT; DRUG INHIBITION; FEMALE; GLUCOSE BLOOD LEVEL; GLYCATION; INCUBATION TIME; KETOACIDOSIS; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEINURIA; RAT; STREPTOZOCIN DIABETES;

ADMINISTRATION, ORAL; ALBUMINURIA; ANIMALS; BLOOD GLUCOSE; BODY WEIGHT; CATARACT; CITRIC ACID; CRYSTALLINS; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 1; GLYCOSYLATION END PRODUCTS, ADVANCED; KETOSIS; RATS; RATS, WISTAR; STREPTOZOCIN;

ANIMALIA; CITRUS LIMON; RATTUS;

EID: 77249139924     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2010.01.095     Document Type: Article

References (24)

1. Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes 54 (2005) 1615-1625
2. Calcutt N.A., Cooper M.E., Kern T.S., and Schmidt A.M. Therapies for hyperglycaemia-induced diabetic complications: from animal models to clinical trials. Nat. Rev. Drug Discov. 8 (2009) 417-429
3. Cooper G.J., Young A.A., Gamble G.D., Occleshaw C.J., Dissanayake A.M., Cowan B.R., Brunton D.H., Baker J.R., Phillips A.R., Frampton C.M., Poppitt S.D., and Doughty R.N. A copper(II)-selective chelator ameliorates left-ventricular hypertrophy in type 2 diabetic patients: a randomised placebo-controlled study. Diabetologia 52 (2009) 715-722
4. Price D.L., Rhett P.M., Thorpe S.R., and Baynes J.W. Chelating activity of advanced glycation end-product inhibitors. J. Biol. Chem. 276 (2001) 48967-48972
5. Wihler C., Schafer S., Schmid K., Deemer E.K., Munch G., Bleich M., Busch A.E., Dingermann T., Somoza V., Baynes J.W., and Huber J. Renal accumulation and clearance of advanced glycation end-products in type 2 diabetic nephropathy: effect of angiotensin-converting enzyme and vasopeptidase inhibition. Diabetologia 48 (2005) 1645-1653
6. Miyata T., van Ypersele de Strihou C., Ueda Y., Ichimori K., Inagi R., Onogi H., Ishikawa N., Nangaku M., and Kurokawa K. Angiotensin II receptor antagonists and angiotensin-converting enzyme inhibitors lower in vitro the formation of advanced glycation end products: biochemical mechanisms. J. Am. Soc. Nephrol. 13 (2002) 2478-2487
7. Penniston K.L., Nakada S.Y., Holmes R.P., and Assimos D.G. Quantitative assessment of citric acid in lemon juice, lime juice, and commercially-available fruit juice products. J. Endourol. 22 (2008) 567-570
8. Alderson N.L., Chachich M.E., Frizzell N., Canning P., Metz T.O., Januszewski A.S., Youssef N.N., Stitt A.W., Baynes J.W., and Thorpe S.R. Effect of antioxidants and ACE inhibition on chemical modification of proteins and progression of nephropathy in the streptozotocin diabetic rat. Diabetologia 47 (2004) 1385-1395
9. Dong X., Ayala M., Lofgren S., and Soderberg P.G. Ultraviolet radiation-induced cataract: age and maximum acceptable dose. Invest. Ophthalmol. Vis. Sci. 44 (2003) 1150-1154
10. Nagai R., Brock J.W., Blatnik M., Baatz J.E., Bethard J., Walla M.D., Thorpe S.R., Baynes J.W., and Frizzell N. Succination of protein thiols during adipocyte maturation: a biomarker of mitochondrial stress. J. Biol. Chem. 282 (2007) 34219-34228
11. Nagai R., Fujiwara Y., Mera K., Yamagata K., Sakashita N., and Takeya M. Immunochemical detection of Nepsilon-(carboxyethyl)lysine using a specific antibody. J. Immunol. Methods 332 (2008) 112-120
12. Nagai R., Hayashi C.M., Xia L., Takeya M., and Horiuchi S. Identification in human atherosclerotic lesions of GA-pyridine, a novel structure derived from glycolaldehyde-modified proteins. J. Biol. Chem. 277 (2002) 48905-48912
13. Lebovitz H.E. Diabetic ketoacidosis. Lancet 345 (1995) 767-772
14. Avogaro A., Calo L., Piarulli F., Miola M., deKreutzenberg S., Maran A., Burlina A., Mingardi R., Tiengo A., and Del Prato S. Effect of acute ketosis on the endothelial function of type 1 diabetic patients: the role of nitric oxide. Diabetes 48 (1999) 391-397
15. Jain S.K., and McVie R. Hyperketonemia can increase lipid peroxidation and lower glutathione levels in human erythrocytes in vitro and in type 1 diabetic patients. Diabetes 48 (1999) 1850-1855
16. Vignati L. Insulin pumps: when are they indicated, what can they do?. Trans. Assoc. Life Insur. Med. Dir. Am. 68 (1985) 53-60
17. Degenhardt T.P., Alderson N.L., Arrington D.D., Beattie R.J., Basgen J.M., Steffes M.W., Thorpe S.R., and Baynes J.W. Pyridoxamine inhibits early renal disease and dyslipidemia in the streptozotocin-diabetic rat. Kidney Int. 61 (2002) 939-950
18. Pajor A.M. Citrate transport by the kidney and intestine. Semin. Nephrol. 19 (1999) 195-200
19. Swamy-Mruthinti S., Green K., and Abraham E.C. Inhibition of cataracts in moderately diabetic rats by aminoguanidine. Exp. Eye Res. 62 (1996) 505-510
20. Padival S., and Nagaraj R.H. Pyridoxamine inhibits maillard reactions in diabetic rat lenses. Ophthalmic Res. 38 (2006) 294-302
21. Krebs H. Biochemical aspects of ketosis. Proc. R. Soc. Med. 53 (1960) 71-80
22. Fasella P., Turano C., Baglioni C., and Siliprandi N. Action of citrate and oxalacetate on dietary and diabetic ketosis. Lancet 1 (1958) 1097
23. Dhar A., Desai K., Kazachmov M., Yu P., and Wu L. Methylglyoxal production in vascular smooth muscle cells from different metabolic precursors. Metabolism 57 (2008) 1211-1220
24. Mitchell G.A., Kassovska-Bratinova S., Boukaftane Y., Robert M.F., Wang S.P., Ashmarina L., Lambert M., Lapierre P., and Potier E. Medical aspects of ketone body metabolism. Clin. Invest. Med. 18 (1995) 193-216